ReviewBlood cancer journal2018
Biological determinants of health disparities in multiple myeloma.
Review in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05874193 (A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Who cites it
22 citing papers in PubMed.
- Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study.The oncologist · 2026Article
- Trends in multiple myeloma and cardiovascular disease-related mortality among older adults in the United States, 1999 to 2023: a CDC wonder database analysis.Annals of medicine and surgery (2012) · 2025Review
- Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.Current oncology (Toronto, Ont.) · 2025Review
- Incidence and trends of multiple myeloma (MM) in Brazil - 1988-2020.Ecancermedicalscience · 2025Article
- Multiple myeloma incidence and mortality trends in the United States, 1999-2020.Scientific reports · 2024Article
- Article
- Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study.Blood cancer journal · 2022Article
- Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.Expert review of molecular diagnostics · 2021Review
- Article
- Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Cancer epidemiology · 2021Article
- Flower-Like Plasma Cell Nuclei in Multiple MyelomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- An overview of cancer health disparities: new approaches and insights and why they matter.Carcinogenesis · 2021Review
- Health Equity Among Black Women in the United States.Journal of women's health (2002) · 2021Article
- Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.Frontiers in immunology · 2021Review
- Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016.Cancer medicine · 2021Article
- Article
- Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.Blood cancer journal · 2020Observational
- Article
- Racial disparities, cancer and response to oxidative stress.Advances in cancer research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Multiple myeloma is a rare plasma cell cancer, and incidence rates among patients of African descent are about twice those among patients of European descent. Rates of multiple myeloma vary among different populations, but the reasons for the racial disparities in multiple myeloma are largely unknown. Epidemiology has identified risk factors for multiple myeloma including race, advanced age, gender, family history, and exposure to different genetic toxins including radiation. Race and ancestry play a large role in predicting the risk for multiple myeloma, yet there exists a paucity of literature that explores the molecular contribution of race and ancestry to disease. In this review, we describe the relevant literature that describes the observed racial differences according to distinct tumor immunobiological and ancestral differences in populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.